2nd Floor 2 Redman Place

London E20 1JQ

United Kingdom

+44 (0)300 323 0140

Sent by e-mail only: XXXXXXXXXXXXXXXXXXX

3 October 2023

Dear Jacoline

Re: Final Draft Guidance (FDG) - belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more prior therapies [ID2701]

I can confirm that I have received your letter dated 2 October notifying that the FDG for belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701] will be withdrawn. On this basis I note that the appeal hearing scheduled for 2 November will not therefore take place.

The appeals team will now write to the appeal panel and appellants advising of the cancellation and will be in touch with the project team regarding the next steps.

Yours sincerely

 XXXXXXXXXXXXXXXXXXXXXXX

Dr Mark Chakravarty

Lead Non-Executive Director for Appeals & Vice Chairman National Institute for Health and Care Excellence

